Literature DB >> 4020465

Juvenile pilocytic astrocytoma of the cerebrum in adults. A distinctive neoplasm with favorable prognosis.

D M Garcia, K H Fulling.   

Abstract

Seven adults (15 years of age or older) with juvenile pilocytic astrocytoma of the cerebrum were treated at Barnes Hospital in St. Louis, Missouri, from 1950 to 1981. This group comprised 7% of the total adult population with well differentiated astrocytoma and astrocytoma with anaplastic foci treated over a 30-year period. All seven patients were less than 30 years old at the time of presentation. The tumors were characterized by distinctive histology, a predilection for the temporal lobe, the presence of a major cyst, and relative gross circumscription making total surgical resection feasible. In contrast to patients with diffusely infiltrating cerebral astrocytoma, those with juvenile pilocytic astrocytoma have had an extremely favorable course, regardless of treatment. Four were treated with surgery alone after total gross tumor excision, and three received postoperative irradiation after subtotal excision. Six were alive 27, 24, 17, 9, 5, and 2 years after initial surgery. One patient died 7 years after surgery and radiation as a result of cerebral radiation necrosis. Juvenile pilocytic astrocytoma of the cerebrum is a recognizable, distinctive entity with natural history and pathological characteristics similar to the relatively benign cerebellar astrocytoma of childhood.

Entities:  

Mesh:

Year:  1985        PMID: 4020465     DOI: 10.3171/jns.1985.63.3.0382

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  14 in total

1.  Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.

Authors:  Derek R Johnson; Paul D Brown; Evanthia Galanis; Julie E Hammack
Journal:  J Neurooncol       Date:  2012-02-25       Impact factor: 4.130

Review 2.  Gliomas in adults.

Authors:  Thomas Schneider; Christian Mawrin; Cordula Scherlach; Martin Skalej; Raimund Firsching
Journal:  Dtsch Arztebl Int       Date:  2010-11-12       Impact factor: 5.594

3.  Management of pilocytic astrocytoma.

Authors:  T Kayama; T Tominaga; T Yoshimoto
Journal:  Neurosurg Rev       Date:  1996       Impact factor: 3.042

4.  Prognostic parameters in benign astrocytomas.

Authors:  L Westergaard; F Gjerris; L Klinken
Journal:  Acta Neurochir (Wien)       Date:  1993       Impact factor: 2.216

Review 5.  Current treatment of thalamic gliomas in children.

Authors:  M M Souweidane; H J Hoffman
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

Review 6.  The impact of technical adjuncts in the surgical management of cerebral hemispheric low-grade gliomas of childhood.

Authors:  M S Berger
Journal:  J Neurooncol       Date:  1996 May-Jun       Impact factor: 4.130

7.  Rapid recurrence and malignant transformation of pilocytic astrocytoma in adult patients.

Authors:  Jason A Ellis; Allen Waziri; Casilda Balmaceda; Peter Canoll; Jeffrey N Bruce; Michael B Sisti
Journal:  J Neurooncol       Date:  2009-06-17       Impact factor: 4.130

8.  Spectroscopy of untreated pilocytic astrocytomas: do children and adults share some metabolic features in addition to their morphologic similarities?

Authors:  Luciana Porto; Matthias Kieslich; Kea Franz; Thomas Lehrbecher; Stefan Vlaho; Ulrich Pilatus; Elke Hattingen
Journal:  Childs Nerv Syst       Date:  2009-12-20       Impact factor: 1.475

9.  Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery.

Authors:  M Scerrati; R Roselli; M Iacoangeli; A Pompucci; G F Rossi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

10.  Stereotactic radiosurgery for pilocytic astrocytomas part 2: outcomes in pediatric patients.

Authors:  Hideyuki Kano; Ajay Niranjan; Douglas Kondziolka; John C Flickinger; Ian F Pollack; Regina I Jakacki; L Dade Lunsford
Journal:  J Neurooncol       Date:  2009-05-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.